Collegium Pharmaceutical Inc (COLL)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 59.76% | 62.36% | 61.94% | 60.01% | 57.55% | 51.46% | 48.40% | 45.41% | 45.15% | 43.79% | 46.46% | 52.59% | 54.40% | 60.24% | 60.81% | 61.16% | 58.01% | 52.17% | 45.96% | 39.06% |
| Operating profit margin | 26.91% | 32.29% | 35.32% | 33.83% | 29.46% | 13.71% | 9.39% | 4.93% | -1.89% | -3.47% | -6.02% | -4.97% | 6.37% | 20.49% | 22.15% | 22.53% | 18.14% | 12.62% | 4.26% | -2.91% |
| Pretax margin | 15.61% | 21.36% | 24.49% | 22.92% | 13.36% | 3.88% | -1.14% | -5.82% | -6.22% | -16.57% | -16.69% | -12.71% | -1.22% | 13.13% | 13.89% | 13.26% | 8.90% | 5.88% | 0.15% | -4.21% |
| Net profit margin | 10.96% | 14.78% | 17.32% | 16.46% | 8.50% | 1.65% | -2.08% | -5.59% | -5.39% | -11.84% | -11.24% | 15.68% | 25.83% | 31.77% | 32.73% | 13.06% | 8.63% | 5.71% | 0.07% | -4.21% |
Collegium Pharmaceutical Inc has shown a fluctuating trend in its profitability ratios over the periods provided. The gross profit margin has generally improved from 39.06% in March 2020 to a peak of 62.36% in September 2024, signifying better efficiency in generating revenue after accounting for the cost of goods sold.
The operating profit margin started in negative territory at -2.91% in March 2020, then gradually increased, reaching a peak of 35.32% in June 2024. This indicates an improvement in the company's ability to control operating expenses and generate profit from its core operations.
The pretax margin shows a similar pattern, starting from -4.21% in March 2020 and peaking at 24.49% in June 2024. This ratio reflects Collegium Pharmaceutical's ability to generate profit before accounting for taxes, showing a positive trend over the years.
The net profit margin also displays fluctuations, beginning at -4.21% in March 2020, reaching a high of 32.73% in June 2021, and then slightly declining to 10.96% in December 2024. This ratio indicates the company's overall profitability after all expenses, including taxes, have been deducted.
Overall, Collegium Pharmaceutical Inc has shown improvements in its profitability ratios over the years, with some variability in performance from period to period. It is essential for stakeholders to monitor these ratios to assess the company's financial health and performance.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 10.21% | 11.83% | 19.33% | 17.21% | 14.60% | 6.37% | 4.15% | 2.13% | -0.75% | -1.05% | -1.52% | -1.09% | 2.55% | 9.00% | 10.12% | 11.20% | 8.73% | 6.04% | 1.99% | -1.37% |
| Return on assets (ROA) | 4.16% | 5.42% | 9.48% | 8.37% | 4.21% | 0.77% | -0.92% | -2.42% | -2.13% | -3.57% | -2.83% | 3.43% | 10.33% | 13.95% | 14.96% | 6.50% | 4.16% | 2.73% | 0.03% | -1.98% |
| Return on total capital | 10.37% | 84.77% | 98.89% | 94.15% | 81.40% | 59.18% | 38.24% | 26.84% | 17.64% | -6.36% | -9.55% | -6.92% | 8.69% | 26.59% | 28.54% | 42.57% | 30.35% | 22.80% | 8.90% | -5.08% |
| Return on equity (ROE) | 4.16% | 37.82% | 46.12% | 41.99% | 24.64% | 5.04% | -5.56% | -16.33% | -12.83% | -21.72% | -17.84% | 21.82% | 35.24% | 41.22% | 42.18% | 24.68% | 14.38% | 10.19% | 0.13% | -8.91% |
Collegium Pharmaceutical Inc's profitability ratios have shown varying trends over the reported periods.
1. Operating Return on Assets (Operating ROA) has fluctuated over time, starting at a negative 1.37% in March 2020, reaching a peak of 19.33% in June 2024, and then declining to 10.21% by December 2024.
2. Return on Assets (ROA) also exhibited fluctuations, with a low of -3.57% in September 2022 and a high of 9.48% in June 2024. These ratios generally improved from negative values in early reporting periods to positive figures by mid-2023 and beyond.
3. Return on Total Capital started at a negative 5.08% in March 2020, peaked at 98.89% in June 2024, and decreased to 10.37% by December 2024. The trend shows significant improvement in profitability from negative figures to high positive returns by the end of the reporting period.
4. Return on Equity (ROE) also experienced fluctuations, representing a pattern of improvement over time. Starting from negative values, ROE increased to reach a peak of 46.12% in June 2024 before declining to 4.16% by December 2024.
Overall, the company's profitability ratios indicate a mixed performance, with some periods showing substantial growth in profitability metrics, while others experienced declines or fluctuations. It is essential for stakeholders to closely monitor these ratios to assess Collegium Pharmaceutical Inc's financial health and performance in the market.